European CHMP recommends extension of delamanid (Deltyba) indication to include treatment of adolescents and children with weight ≥30 kg

Deltyba is currently licensed for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adults when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.


European Medicines Agency